Literature DB >> 9028939

Impaired hematopoiesis in paroxysmal nocturnal hemoglobinuria/aplastic anemia is not associated with a selective proliferative defect in the glycosylphosphatidylinositol-anchored protein-deficient clone.

J P Maciejewski1, E M Sloand, T Sato, S Anderson, N S Young.   

Abstract

Paroxysmal nocturnal hemoglobinuria (PNH) results from somatic mutations in the PIG-A gene, leading to poor presentation of glycosylphosphatidylinositol (GPI)-anchored surface proteins. PNH frequently occurs in association with suppressed hematopoiesis, including frank aplastic anemia (AA). The relationship between GPI-anchored protein expression and bone marrow (BM) failure is unknown. To assess the hematopoietic defect in PNH, the numbers of CD34+ cells, committed progenitors (primary colony-forming cells [CFCs]), and long-term culture-initiating cells (LTC-ICs; a stem cell surrogate) were measured in BM and peripheral blood (PB) of patients with PNH/AA syndrome or patients with predominantly hemolytic PNH. LTC-IC numbers were extrapolated from secondary CFC numbers after 5 weeks of culture, and clonogenicity of LTC-ICs was determined by limiting dilution assays. When compared with normal volunteers (n = 13), PNH patients (n = 14) showed a 4.7-fold decrease in CD34+ cells and an 8.2-fold decrease in CFCs. LTC-ICs in BM and in PB were decreased 7.3-fold and 50-fold, respectively. Purified CD34+ cells from PNH patients had markedly lower clonogenicity in both primary colony cultures and in the LTC-IC assays. As expected, GPI-anchored proteins were decreased on PB cells of PNH patients. On average, 23% of monocytes were deficient in CD14, and 47% of granulocytes and 58% of platelets lacked CD16 and CD55, respectively. In PNH BM, 27% of CD34+ cells showed abnormal GPI-anchored protein expression when assessed by CD59 expression. To directly measure the colony-forming ability of GPI-anchored protein-deficient CD34+ cells, we separated CD34+ cells from PNH patients for the GPI+ and GPI-phenotype; CD59 expression was chosen as a marker of the PNH phenotype based on high and homogeneous expression on fluorescent staining. CD34+ CD59+ and CD34+ CD59-cells from PNH/AA patients showed similarly impaired primary and secondary clonogeneic efficiency. The progeny derived from CD34+ CD59- cells were both CD59- and CD55-. A very small population of CD34+ CD59- cells was also detected in some normal volunteers; after sorting, these CD34+ CD59- cells formed normal numbers of colonies, but their progeny showed lower CD59 levels. Our results are consistent with the existence of PIG-A-deficient clones in some normal individuals. In PNH/AA, progenitor and stem cells are decreased in number and function, but the proliferation in vitro is affected similarly in GPI-protein-deficient clones and in phenotypically normal cells. As measured in the in vitro assays, expansion of PIG-A- clones appears not be caused by an intrinsic growth advantage of cells with the PNH phenotype.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9028939

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  26 in total

1.  Genetic and environmental effects in paroxysmal nocturnal hemoglobinuria: this little PIG-A goes "Why? Why? Why?".

Authors:  N S Young; J P Maciejewski
Journal:  J Clin Invest       Date:  2000-09       Impact factor: 14.808

Review 2.  Pathogenesis of selective expansion of PNH clones.

Authors:  Hideki Nakakuma; Tatsuya Kawaguchi
Journal:  Int J Hematol       Date:  2003-02       Impact factor: 2.490

3.  Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals.

Authors:  D J Araten; K Nafa; K Pakdeesuwan; L Luzzatto
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

Review 4.  New insights into molecular pathogenesis of bone marrow failure in paroxysmal nocturnal hemoglobinuria.

Authors:  Tatsuya Kawaguchi; Hideki Nakakuma
Journal:  Int J Hematol       Date:  2007-07       Impact factor: 2.490

Review 5.  Senescence of hematopoietic stem cells and bone marrow failure.

Authors:  Jichun Chen
Journal:  Int J Hematol       Date:  2005-10       Impact factor: 2.490

Review 6.  Paroxysmal nocturnal hemoglobinuria: a complement-mediated hemolytic anemia.

Authors:  Amy E DeZern; Robert A Brodsky
Journal:  Hematol Oncol Clin North Am       Date:  2015-03-07       Impact factor: 3.722

7.  Long-term outcome of fludarabine-based reduced-intensity allogeneic hematopoietic cell transplantation for debilitating paroxysmal nocturnal hemoglobinuria.

Authors:  Jeremy Pantin; Xin Tian; Nancy Geller; Catalina Ramos; Lisa Cook; Elena Cho; Phillip Scheinberg; Sumithira Vasu; Hahn Khuu; David Stroncek; John Barrett; Neal S Young; Theresa Donohue; Richard W Childs
Journal:  Biol Blood Marrow Transplant       Date:  2014-05-17       Impact factor: 5.742

8.  Sustained clonal hematopoiesis by HLA-lacking hematopoietic stem cells without driver mutations in aplastic anemia.

Authors:  Tatsuya Imi; Takamasa Katagiri; Kazuyoshi Hosomichi; Yoshitaka Zaimoku; Viet Hoang Nguyen; Noriharu Nakagawa; Atsushi Tajima; Tetsuichi Yoshizato; Seishi Ogawa; Shinji Nakao
Journal:  Blood Adv       Date:  2018-05-08

9.  Paroxysmal nocturnal hemoglobinuria: pathophysiology, natural history and treatment options in the era of biological agents.

Authors:  Antonio M Risitano; Bruno Rotoli
Journal:  Biologics       Date:  2008-06

10.  The pathophysiology of paroxysmal nocturnal hemoglobinuria and treatment with eculizumab.

Authors:  Richard Kelly; Stephen Richards; Peter Hillmen; Anita Hill
Journal:  Ther Clin Risk Manag       Date:  2009       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.